Merck Wins EU Approval for KEYTRUDA Combo in Ovarian Cancer
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
